Regeneron Pharmaceuticals has been named to the Dow Jones Best-in-Class World Index for the seventh consecutive year, recognizing its leadership in corporate responsibility. The company is also on the Dow Jones Best-in-Class North America Index for the sixth year. This recognition reflects Regeneron's dedication to responsible innovation, including offering a new gene therapy for genetic hearing loss free in the U.S. Regeneron has set new 2030 science-led responsibility goals and continues to invest heavily in STEM education and initiatives to address inequities in genomics research. These efforts underscore its commitment to sustainable growth and patient access to transformative medicines.
